GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (NAS:XAIR) » Definitions » ROIC %

XAIR (Beyond Air) ROIC % : -287.77% (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Beyond Air ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Beyond Air's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2024 was -287.77%.

As of today (2024-12-14), Beyond Air's WACC % is 10.57%. Beyond Air's ROIC % is -371.31% (calculated using TTM income statement data). Beyond Air earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Beyond Air ROIC % Historical Data

The historical data trend for Beyond Air's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beyond Air ROIC % Chart

Beyond Air Annual Data
Trend Jun15 Jun16 Dec17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -460.18 -520.82 -439.45 -515.21 -497.53

Beyond Air Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -621.19 -540.82 -361.60 -346.13 -287.77

Competitive Comparison of Beyond Air's ROIC %

For the Medical Devices subindustry, Beyond Air's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beyond Air's ROIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's ROIC % distribution charts can be found below:

* The bar in red indicates where Beyond Air's ROIC % falls into.



Beyond Air ROIC % Calculation

Beyond Air's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Mar. 2024 is calculated as:

ROIC % (A: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2023 ) + Invested Capital (A: Mar. 2024 ))/ count )
=-63.007 * ( 1 - 0% )/( (10.673 + 14.655)/ 2 )
=-63.007/12.664
=-497.53 %

where

Beyond Air's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2024 is calculated as:

ROIC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-51.328 * ( 1 - 0% )/( (16.732 + 18.941)/ 2 )
=-51.328/17.8365
=-287.77 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beyond Air  (NAS:XAIR) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Beyond Air's WACC % is 10.57%. Beyond Air's ROIC % is -371.31% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Beyond Air ROIC % Related Terms

Thank you for viewing the detailed overview of Beyond Air's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Beyond Air Business Description

Traded in Other Exchanges
Address
900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Executives
Robert Carey director HORIZON PHARMA, INC., 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60062
Steven A. Lisi director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Amir Avniel director, officer: President & CEO 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jeff Lynn Myers officer: Chief Medical Officer C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Michael A. Gaul officer: Chief Operating Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
William P Forbes director C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Yoori Lee director C/O AIT THERAPEUTICS, INC., 500 MAMARONECK AVENUE, HARRISON NY 10528
Ron Bentsur director 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Douglas Quinton Larson officer: Chief Financial Officer BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Douglas Beck officer: Chief Financial Officer C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Ari Raved director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
David Grossman director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Haim Aviv officer: Chief Financial Officer 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635